$2.41
+0.11 (+4.78%)
Open$2.35
Previous Close$2.30
Day High$2.48
Day Low$2.27
52W High$4.53
52W Low$1.65
Volume—
Avg Volume295.0K
Market Cap77.29M
P/E Ratio11.34
EPS$0.17
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+436.5% upside
Current
$2.41
$2.41
Target
$12.93
$12.93
$7.67
$12.93 avg
$16.62
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 73.32M | 77.85M | 15.02M |
| Net Income | 7.90M | 7.55M | -500,427 |
| Profit Margin | 10.8% | 10.2% | -3.3% |
| EBITDA | -24,637,791 | -24,852,305 | -867,054 |
| Free Cash Flow | — | — | -309,659 |
| Rev Growth | -5.8% | -5.8% | +23.3% |
| Debt/Equity | 1.19 | 1.19 | 0.77 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |